On Tuesday, Danish pharmaceutical leader Novo Nordisk and privately held Canadian biotech Aspect Biosystems announced an expanded collaboration to co-develop cell-based therapies targeting type 1 and advanced type 2 diabetes. Under the terms, Novo Nordisk will provide up to $50 million in research funding and gain options to license two preclinical programs—one focused on microencapsulated islet cells and another on engineered immunomodulatory cells designed to protect transplanted islets from autoimmune attack. The extension builds on a 2022 agreement, adds dedicated manufacturing support at Novo Nordisk’s facility in Måløv, and sets joint milestones through 2028, positioning the partners to enter first-in-human trials by 2030 if preclinical safety and efficacy endpoints are met.

Following its early January launch, Novo Nordisk’s oral formulation of the GLP-1 agonist Wegovy recorded exceptionally strong uptake in the U.S., with retail pharmacies reporting over 25,000 first-week prescriptions and payers approving more than 80% of patient access requests in week one. The company’s U.S. market share for obesity treatments rose by 3 percentage points in the first month, prompting investors to drive the stock up 9.1% in a single session. Analysts note that the pill’s ease of use compared with injectable competitors and coverage by three of the five largest U.S. pharmacy benefit managers are key drivers of early adoption, setting the stage for potential double-digit revenue growth in the second quarter.